In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Generics
The Indian pharma and healthcare sector has witnessed a 298% jump in deals during the third quarter of 2023 compared to the same period last year. 8 November 2023
Pharmaceutical
Across pharma companies, teams invest so much time and resources in engaging with their key customers, whether it be at congresses or one-on-one meetings with Key Opinion Leaders (KOLs), and have such a plethora of data surrounding these activities and interactions, that recording and making sense of it all—let alone maximizing the value of engagements according to organizational objectives—can seem a near impossible challenge. 7 November 2023
Biotechnology
South Korea’s Chong Kun Dang Pharmaceutical's stock soared 26.1% to end at 128,000 won on Monday, on news of a deal with Swiss pharma giant Novartis. 7 November 2023
Biotechnology
A biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer, is to go by a new name. 7 November 2023
Pharmaceutical
The European Federation of Pharmaceutical Industries and Associations (EFPIA) is not happy. 7 November 2023
Pharmaceutical
Indian drugmakers Lupin and Zydus Lifesciences have entered into a licensing and supply agreement to co-market, saroglitazar Mg for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in India. 7 November 2023
Biotechnology
A collaboration between Senti Biosciences and Celest Therapeutics will see the latter gain rights to develop SENTI-301A in China. 7 November 2023
Biotechnology
Having previously had disappointing results from its investigational drug, Kodiak Sciences yesterday announced that its Phase III GLOW superiority study evaluating tarcocimab tedromer 5mg in moderately severe to severe non-proliferative diabetic retinopathy (NPDR) met its one-year primary endpoint. 7 November 2023
Pharmaceutical
Swiss pharma giant Roche announced the sector's biggest pharma M&A deal in October. 7 November 2023
Pharmaceutical
German pharma major Bayer has revealed it is expanding its Phase III OCEANIC clinical development program for the investigational drug asundexain (BAY2433334) by initiating a third clinical study, OCEANIC-AFINA. 7 November 2023
Pharmaceutical
UK-headquartered specialty pharmaceutical company Advanz Pharma today announced it expands its specialty brands portfolio with the signing of the acquisition of global rights of Androcur (cyproterone acetate) from German pharma major Bayer. 7 November 2023
Pharmaceutical
American biopharma company Vertex Pharmaceuticals has announced strong third quarter financial results and raised its guidance for product revenues in 2023. 7 November 2023
Biotechnology
San Mateo, USA-based biotech start-up Cargo Therapeutics, which is specializing in cancer treatments, set terms for its initial public offering (IPO) early Monday with plans to offer 18.8 million shares priced at $15 to $17 each. 7 November 2023
Pharmaceutical
Swedish nephrology company Calliditas Therapeutics has highlighted new analyses from the Phase III NefIgArd study. 7 November 2023
Pharmaceutical
Anastrozole, which has been used for many years as a breast cancer treatment, has today been licensed by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a preventive option – which it is hoped could help prevent around 2,000 cases of breast cancer in England. 7 November 2023
Biotechnology
Acelyrin has appointed Patricia Turney as chief technical operations officer. 6 November 2023
Biotechnology
Kronos Bio is to cut around 19% of its staff as part of a plan to extend its cash runway into 2026. 6 November 2023
Biotechnology
Shares of German biotech BioNTech were up 5.3% at $100.91, despite joining the list of companies with downturned sales and earnings as the COVID-19 pandemic subsides. 6 November 2023
Pharmaceutical
Thomas Cueni, the director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and secretary of the Biopharmaceutical CEO Roundtable (BCR), is set to retire in April 2024. 6 November 2023
Biotechnology
Halozyme Therapeutics today announced a global collaboration and non-exclusive license agreement with fellow US biotech Acumen Pharmaceuticals. 6 November 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze